Stock Market & Financial Investment News

News Breaks January 17, 2013 06:50 EDT BIO Bio-Rad upgraded to Outperform from Underperform at CLSA CLSA upgraded Bio-Rad based on earnings leverage, consistent diagnostics growth, ERP completion, easier currency comps, and exposure to Asia. Price target raised to $124 form $103 News For BIO From The Last 14 Days Check below for free stories on BIO the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for BIO Sign up for a free trial to see the rest of the stories you've been missing.